CTOs on the Move

Fujifilm Diosynth Biotechnologies

www.fujifilmdiosynth.com

 
As a CDMO our focus is to combine technical leadership in cell culture, microbial fermentation and viral vectors with world class cGMP manufacturing facilities to advance tomorrow`s medicines. For over 25 years our focus has been on supporting our customers with the development and manufacture of recombinant proteins, viral vaccines and gene therapies.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Mike Tomasco
Senior Vice President - Chief Information Officer Profile

Similar Companies

Dendritic NanoTechnologies

Dendritic NanoTechnologies is a Mount Pleasant, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prime Medicine

Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations.

Stolle Milk Biologics Inc

Stolle Milk Biologics Inc is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carterra

Carterra, formerly Wasatch Microfluidics, develops high throughput surface plasmon resonance array-based platforms for biomolecular interaction analysis.

Denali Therapeutics

Denali Therapeutics Inc. (“Denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).